Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anne Reifel-Miller is active.

Publication


Featured researches published by Anne Reifel-Miller.


Journal of Cellular Physiology | 2007

Molecular determinants of FGF-21 activity : Synergy and cross-talk with PPARγ signaling

Julie S. Moyers; Tatiyana L. Shiyanova; Farrokh Mehrbod; James D. Dunbar; Timothy Wayne Noblitt; Keith A. Otto; Anne Reifel-Miller; Alexei Kharitonenkov

Fibroblast growth factor (FGF)‐21 is a novel regulator of insulin‐independent glucose transport in 3T3‐L1 adipocytes and has glucose and triglyceride lowering effects in rodent models of diabetes. The precise mechanisms whereby FGF‐21 regulates metabolism remain to be determined. Here we describe the early signaling events triggered by FGF‐21 treatment of 3T3‐L1 adipocytes and reveal a functional interplay between FGF‐21 and peroxisome proliferator‐activated receptor gamma (PPARγ) pathways that leads to a marked stimulation of glucose transport. While the early actions of FGF‐21 on 3T3‐L1 adipocytes involve rapid accumulation of intracellular calcium and phosphorylation of Akt, GSK‐3, p70S6K, SHP‐2, MEK1/2, and Stat3, continuous treatment for 72 h induces an increase in PPARγ protein expression. Moreover, chronic activation of the PPARγ pathway in 3T3‐L1 adipocytes with the PPARγ agonist and anti‐diabetic agent, rosiglitazone (BRL 49653), enhances FGF‐21 action to induce tyrosine phosphorylation of FGF receptor‐2. Strikingly, treatment of cells with FGF‐21 and rosiglitazone in combination leads to a pronounced increase in expression of the GLUT1 glucose transporter and a marked synergy in stimulation of glucose transport. Together these results reveal a novel synergy between two regulators of glucose homeostasis, FGF‐21 and PPARγ, and further define FGF‐21 mechanism of action. J. Cell. Physiol. 210: 1–6, 2007.


Bioorganic & Medicinal Chemistry Letters | 2003

Design and synthesis of fluorinated RXR modulators.

D.L. Gernert; R. Ajamie; R.A. Ardecky; Michael Gregory Bell; Mark D. Leibowitz; Dale A. Mais; Christopher M. Mapes; P.Y. Michellys; Deepa Rungta; Anne Reifel-Miller; John S. Tyhonas; Nathan Yumibe; Timothy Alan Grese

Fluorinated trienoic acid analogues of the RXR selective modulator 1 (LG101506) were synthesized, and tested for their ability to bind RXRalpha and activate RXR homo and heterodimers. Potency and efficacy were observed to be dependent upon the position of fluorination, and improvement in pharmacological profile was demonstrated in some cases.


Nature Genetics | 1999

Experimental designs using Affymetrix GeneChips

Chi-Hse Teng; Ann Nestorowicz; Anne Reifel-Miller

We are developing sets of mouse cDNAs with low redundancy for use in microarray analysis. The sets are based on sequence information from GenBank and the Washington University/Merck EST sequencing project. Related sequences from the non-redundant GenBank database were compared with mouse EST clones from the IMAGE consortium. A single EST for a given cluster was selected, colony purified and sequence validated. To evaluate this set of cDNAs for its use in differential gene expression studies, we generated cDNA microarrays. Those microarray slides were used in hybridization experiments using samples of the melanocyte-specific lineage of the neural crest as a model system. Gene expression was compared between RNA samples obtained from mouse melanoma tissue samples of a transgenic hepatocyte growth factor/scatter factor melanoma mouse model and a MEF-derived mouse fibroblast cell line (NIH3T3). Applying a confidence level of 99%, 8.5% of the arrayed genes were found to be differentially expressed. The melanocyte lineage marker genes Dct, Pmel17 and Sox10 are overexpressed in the melanoma samples with a ratio of 7.6, 6.9 and 7.8, respectively. A low expression ratio of 0.6 is seen for the fibroblast marker gene fibronectin. Genes encoding ubiquitin and the heat shock protein Hsc73 display no significant expression changes between the two differential samples.


Journal of Biological Chemistry | 2004

Rosiglitazone Induction of Insig-1 in White Adipose Tissue Reveals a Novel Interplay of Peroxisome Proliferator-activated Receptor γ and Sterol Regulatory Element-binding Protein in the Regulation of Adipogenesis

Heidi R. Kast-Woelbern; Sharon L. Dana; Rosemary Cesario; Li Sun; Louise Y. de Grandpre; Mason E. Brooks; Deborah L. Osburn; Anne Reifel-Miller; Kay Klausing; Mark D. Leibowitz


Endocrinology | 2007

Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes.

Yanfang Liu; M. Dodson Michael; Shera Kash; William R. Bensch; Brett P. Monia; Susan F. Murray; Keith A. Otto; Samreen K. Syed; Sanjay Bhanot; Kyle W. Sloop; John M. Sullivan; Anne Reifel-Miller


Biochemical Journal | 1999

Stimulation of pancreatic beta-cell proliferation by growth hormone is glucose-dependent: signal transduction via janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) with no crosstalk to insulin receptor substrate-mediated mitogenic signalling.

Sharon P. Cousin; Sigrun R. Hügl; Martin G. Myers; Morris F. White; Anne Reifel-Miller; Christopher J. Rhodes


Molecular Endocrinology | 2005

A Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia

Anne Reifel-Miller; Keith A. Otto; Eric Hawkins; Robert J. Barr; William R. Bensch; Chris Bull; Sharon Dana; Kay Klausing; Jose-Alfredo Martin; Ronit Rafaeloff-Phail; Chahrzad Rafizadeh-Montrose; Gary A. Rhodes; Roger L. Robey; Isabel Rojo; Deepa Rungta; David Snyder; Kelly L. Wilbur; Tony Y. Zhang; Richard W. Zink; Alan M. Warshawsky; Joseph T. Brozinick


Endocrinology | 2006

Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes

Mark D. Leibowitz; Robert Ardecky; Marcus F. Boehm; Carol L. Broderick; Mark A. Carfagna; Diane L. Crombie; Jennifer D’Arrigo; Garrett J. Etgen; Margaret M. Faul; Timothy Alan Grese; Henry Havel; Nancy I. Hein; Richard A. Heyman; Diane Jolley; Kay Klausing; Sha Liu; Dale E. Mais; Christopher M. Mapes; Keith B. Marschke; Pierre-Yves Michellys; Chahrzad Montrose-Rafizadeh; Kathleen M. Ogilvie; Bernadette Pascual; Deepa Rungta; John S. Tyhonas; Mary S. Urcan; Marilyn Wardlow; Nathan Yumibe; Anne Reifel-Miller


Journal of Medicinal Chemistry | 2003

Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.

Michellys Py; Robert Ardecky; Jyun-Hung Chen; Crombie Dl; Etgen Gj; Margaret M. Faul; Faulkner Al; Timothy Alan Grese; Richard A. Heyman; Donald S. Karanewsky; Klausing K; Leibowitz; Sha Liu; Dale A. Mais; Christopher M. Mapes; Keith B. Marschke; Anne Reifel-Miller; Ogilvie Km; Deepa Rungta; Anthony W. Thompson; John S. Tyhonas; Marcus F. Boehm


Journal of Medicinal Chemistry | 2003

Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.

Pierre-Yves Michellys; Robert Ardecky; Jyun-Hung Chen; Jennifer D'Arrigo; Timothy Alan Grese; Donald S. Karanewsky; Mark D. Leibowitz; Sha Liu; Dale A. Mais; Christopher M. Mapes; Chahrzad Montrose-Rafizadeh; Ogilvie Km; Anne Reifel-Miller; Deepa Rungta; Anthony W. Thompson; and John S. Tyhonas; Marcus F. Boehm

Collaboration


Dive into the Anne Reifel-Miller's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pierre-Yves Michellys

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors

Avatar

Donald S. Karanewsky

Genomics Institute of the Novartis Research Foundation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge